American Century Companies Inc. Acquires 25,740 Shares of Penumbra, Inc. (PEN)

American Century Companies Inc. increased its holdings in shares of Penumbra, Inc. (NYSE:PEN) by 8.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 331,427 shares of the company’s stock after purchasing an additional 25,740 shares during the period. American Century Companies Inc. owned 0.98% of Penumbra worth $29,928,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. First Trust Advisors LP boosted its stake in Penumbra by 811.1% in the second quarter. First Trust Advisors LP now owns 22,113 shares of the company’s stock valued at $1,940,000 after acquiring an additional 19,686 shares in the last quarter. Eagle Asset Management Inc. boosted its stake in Penumbra by 168.7% in the second quarter. Eagle Asset Management Inc. now owns 510,918 shares of the company’s stock valued at $44,833,000 after acquiring an additional 320,794 shares in the last quarter. Vanguard Group Inc. boosted its stake in Penumbra by 2.3% in the second quarter. Vanguard Group Inc. now owns 2,165,995 shares of the company’s stock valued at $190,066,000 after acquiring an additional 47,768 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Penumbra by 7.4% during the first quarter. Geode Capital Management LLC now owns 199,932 shares of the company’s stock worth $16,684,000 after buying an additional 13,788 shares during the period. Finally, Amalgamated Bank acquired a new stake in shares of Penumbra during the first quarter worth $274,000. Hedge funds and other institutional investors own 71.40% of the company’s stock.

Several research firms have recently commented on PEN. downgraded shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. lifted their price objective on shares of Penumbra from $96.00 to $117.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. reiterated a “buy” rating and set a $100.00 price objective (up from $94.00) on shares of Penumbra in a research note on Wednesday, August 9th. Finally, downgraded shares of Penumbra from a “hold” rating to a “sell” rating in a research note on Saturday, August 12th.

In other Penumbra news, EVP Robert D. Evans sold 2,859 shares of Penumbra stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $90.00, for a total value of $257,310.00. Following the completion of the transaction, the executive vice president now owns 11,704 shares of the company’s stock, valued at $1,053,360. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Harpreet Grewal sold 4,500 shares of Penumbra stock in a transaction on Monday, August 21st. The shares were sold at an average price of $82.65, for a total transaction of $371,925.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,898 shares of company stock valued at $3,289,865. 13.50% of the stock is currently owned by corporate insiders.

Shares of Penumbra, Inc. (NYSE PEN) opened at $107.60 on Wednesday. Penumbra, Inc. has a one year low of $57.85 and a one year high of $116.35.

Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.07. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. The firm had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $79.17 million. During the same quarter last year, the company posted ($0.04) earnings per share. The firm’s revenue was up 24.9% compared to the same quarter last year. analysts anticipate that Penumbra, Inc. will post -0.15 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://weekherald.com/2017/11/15/american-century-companies-inc-acquires-25740-shares-of-penumbra-inc-pen.html.

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Institutional Ownership by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply